NewLimit Raises $130M in Series B Funding
Summary
NewLimit, a South San Francisco, CA-based developer of medicines that add healthy years to each human life, raised a $130m Series B funding round. The round was led by Kleiner Perkins alongside new investors Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, and Valor Equity Partners — joined by existing investors Dimension, Founders Fund, Brian Armstrong, John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale, and Garry Tan. The company intends to use the funds to expand operations and its development efforts. Led by Blake Byers and Brian Armstrong, NewLimit is building medicines to treat aging, the meta driver of nearly every major human disease. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable.